Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Jun. 30, 2021 | Jan. 20, 2021 | Dec. 31, 2020 | |
Document Information Line Items | |||
Entity Registrant Name | America Great Health | ||
Document Type | 10-K | ||
Current Fiscal Year End Date | --06-30 | ||
Entity Common Stock, Shares Outstanding | 21,075,888,239 | ||
Entity Public Float | $ 0 | ||
Amendment Flag | false | ||
Entity Central Index Key | 0001098009 | ||
Entity Current Reporting Status | No | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Well-known Seasoned Issuer | No | ||
Document Period End Date | Jun. 30, 2021 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Shell Company | false | ||
Entity Ex Transition Period | false | ||
ICFR Auditor Attestation Flag | true | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity File Number | 000-27873 | ||
Entity Incorporation, State or Country Code | WY | ||
Entity Tax Identification Number | 98-0178621 | ||
Entity Address, Address Line One | 1609 W Valley Blvd Unit 338A | ||
Entity Address, City or Town | Alhambra | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 91803 | ||
City Area Code | 888 | ||
Local Phone Number | 988-1333 | ||
Title of 12(g) Security | Common Stock, no par value | ||
Entity Interactive Data Current | No |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jun. 30, 2021 | Jun. 30, 2020 |
CURRENT ASSETS | ||
Cash | $ 396,136 | $ 166 |
Deposit | 700 | 0 |
Inventory | 7,848 | 1,141 |
Other receivable | 61,136 | 2,587 |
Supplier advances | 17,600 | 0 |
TOTAL CURRENT ASSETS | 483,420 | 3,894 |
Right-of-use asset | 126,927 | 0 |
Property and equipment, net | 12,671 | 0 |
TOTAL ASSETS | 623,018 | 3,894 |
CURRENT LIABILITIES | ||
Accounts payable and accrued expense | 57,209 | 49,273 |
Income tax payable | 800 | 1,600 |
Due to related party | 323,750 | 168,028 |
Lease liability | 50,672 | 0 |
TOTAL CURRENT LIABILITIES | 432,431 | 218,901 |
Lease liability - non current | 76,255 | 0 |
Long term loan | 582,159 | |
TOTAL LIABILITIES | 1,090,845 | 218,901 |
SHAREHOLDERS' DEFICIT | ||
Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding | 0 | 0 |
Common stock, no par value, unlimited shares authorized; 21,070,866,399 and 20,236,021,836 shares issued and outstanding | 0 | 0 |
Additional paid-in capital | 3,087,869 | 3,071,635 |
Accumulated deficit | (3,555,696) | (3,286,642) |
TOTAL SHAREHOLDERS' EQUITY(DEFICIT) | (467,827) | (215,007) |
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | $ 623,018 | $ 3,894 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - shares | Jun. 30, 2021 | Jun. 30, 2020 |
Statement of Financial Position [Abstract] | ||
Series A voting preferred stock, shares issued | 0 | 0 |
Series A voting preferred stock, shares outstanding | 0 | 0 |
Redeemable, convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Common stock, shares issued | 21,070,866,399 | 20,236,021,836 |
Common stock, shares outstanding | 21,070,866,399 | 20,236,021,836 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Income Statement [Abstract] | ||
Sales | $ 195,671 | $ 5,474 |
Cost of goods sold | 144,318 | 3,369 |
Gross profit | 51,353 | 2,105 |
Professional fee | 139,292 | 34,255 |
Payroll expense | 88,100 | 0 |
Rent expense | 39,679 | 0 |
Other | 27,842 | 14,001 |
294,913 | 48,256 | |
Loss from operations | (243,560) | (46,151) |
Loss on equity investment | (5,450) | 0 |
Interest expense | (20,044) | (4,965) |
(25,494) | (4,965) | |
Loss before income taxes | (269,054) | (51,116) |
Income tax provision | 0 | 800 |
NET LOSS | $ (269,054) | $ (51,916) |
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share) | $ 0 | $ 0 |
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED (in Shares) | 20,438,554,050 | 20,236,021,836 |
Consolidated Statement of Share
Consolidated Statement of Shareholders' Equity - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance at Jun. 30, 2019 | $ 3,066,724 | $ (3,234,726) | $ (168,002) | |
Balance (in Shares) at Jun. 30, 2019 | 20,236,021,836 | |||
Imputed Interest | 4,911 | 4,911 | ||
Net loss | (51,916) | (51,916) | ||
Balance at Jun. 30, 2020 | 3,071,635 | (3,286,642) | $ (215,007) | |
Balance (in Shares) at Jun. 30, 2020 | 20,236,021,836 | 20,236,021,836 | ||
Issuance of common stock for compensation | 2,064 | $ 2,064 | ||
Issuance of common stock for compensation (in Shares) | 206,394,563 | |||
Issuance of common stock for debt | 135 | 135 | ||
Issuance of common stock for debt (in Shares) | 13,450,000 | |||
Shares issued for equity trust | 700 | 700 | ||
Shares issued for equity trust (in Shares) | 70,000,000 | |||
Shares issued for merger & acquisition | 5,450 | 5,450 | ||
Shares issued for merger & acquisition (in Shares) | 545,000,000 | |||
Imputed Interest | 7,885 | 7,885 | ||
Net loss | (269,054) | (269,054) | ||
Balance at Jun. 30, 2021 | $ 3,087,869 | $ (3,555,696) | $ (467,827) | |
Balance (in Shares) at Jun. 30, 2021 | 21,070,866,399 | 21,070,866,399 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cash Flows from Operating Activities | ||
Net loss | $ (269,054) | $ (51,916) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock compensation | 2,064 | 0 |
Financing cost | 135 | 0 |
Loss on equity investment | 5,450 | 0 |
Imputed interest | 7,885 | 4,911 |
Other receivable | (58,549) | (2,587) |
Supplier advances | (17,600) | 0 |
Inventory | (6,708) | (1,141) |
Accounts payable and accrued expense | 7,936 | 10,374 |
Income tax payable | (800) | 800 |
Net cash used in operating activities from continuing operations | (329,241) | (39,559) |
Net cash used in operating activities | (329,241) | (39,559) |
Cash Flows from Investing Activities | ||
Purchase of property and equipment | (12,671) | 0 |
Net cash provided by investing activities | (12,671) | 0 |
Cash Flows from Financing Activities | ||
Long term loan | 582,159 | 0 |
Advances from related party | 235,331 | 121,840 |
Repayment to related party | (79,608) | (82,217) |
Net cash provided by financing activities | 737,882 | 39,623 |
Net increase in cash | 395,970 | 64 |
Cash beginning of period | 166 | 102 |
Cash end of period | 396,136 | 166 |
Interest paid | 0 | 0 |
Taxes paid | 800 | 0 |
Non-cash transactions | ||
Shares issued for equity investment | $ 5,450 | $ 0 |
NATURE OF BUSINESS
NATURE OF BUSINESS | 12 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | NOTE 1 NATURE OF BUSINESS History and Organization America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations. On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health. On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California. On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. The company does not have significant control over Purecell.We accounted as equity because we do not have control even own 51%. On February 10, 2021, the Company completed its financial and legal due diligence. This transaction was completed in May 2021. On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology to the JV Company as its capital contribution, to account for 40% equity ownership. In June 2021, the JV Company was established in Hainan, China, fully known as Sijinsai (Hainan) Biological Tech Ltd. On July 9, 2021, the Company paid the first investment of $50,000. Going Concern The accompanying consolidated financial statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2021, the Company recorded a net loss of $269,054, used cash to fund operating activities of $329,241, and at June 30, 2021, had a shareholders’ deficit of $467,827. These factors create substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations. Our cash needs for the 12 months ended June 30, 2021 were primarily met by loans and advances from current majority shareholder. As of June 30, 2021, we had a cash balance of $396,136. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Basis of Consolidation The CFS includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California and US-China Mega Beauty Health Industry development Co., LTD, Intercompany transactions and accounts were eliminated in consolidation. Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates. Cash The Company considers all highly liquid debt instruments purchased with maturity periods of six months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of June 30, 2021 and 2020, the Company’s bank account in the United States had $127,672 and $0, respectively, exceeding FDIC insurance of $250,000. Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. The Company has one major wholesale transaction with a new customer in the year ended June 30, 2021. Sales to this customer accounted for approximately 99% of total sales of the year ended June 30, 2021. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred to the customer as goods are delivered to the third party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed upon delivery to the third party carrier for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the years ended June 30, 2021 and 2020, the Company has not made provision for inventory in regards to slow moving or obsolete items. Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the year ended June 30, 2021. Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2021 and 2020, as there are no potential shares outstanding that would have a dilutive effect. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of June 30, 2021 and 2020. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements. |
OTHER RECEIVABLE
OTHER RECEIVABLE | 12 Months Ended |
Jun. 30, 2021 | |
Receivables [Abstract] | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | NOTE 3 OTHER RECEIVABLE As of June 30, 2021 and 2020, other receivable amounted to $61,136 and $0, respectively. Other receivable consists the following: June 30, 2021 June 30, 2020 Deposit for gas company $ 1,825 $ - Rent deposit 9,311 - Loan to a third party 50,000 - Total $ 61,136 $ - Loan to a third party amounted $50,000 and $0 as of June 30, 2021 and 2020. Loan to a third party is due on July 30, 2021, interest free, no collateral, and interest free. The loan has not been paid back as of the reporting date. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Jun. 30, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | NOTE 4 RELATED PARTY TRANSACTIONS During the year ended June 30, 2021, the Company's current majority shareholder advanced $235,331 to the Company as working capital and the Company repaid $79,608 to the shareholder. As of June 30, 2021 and 2020, the Company owed its current majority shareholder of $323,750 and $168,028 respectively. The advances are non-interest bearing and are due on demand. Imputed interest amounted $7,885 and $4,911 for the years ended June 30, 2021 and 2020 and was recorded as paid in capital, respectively. |
LONG TERM LOAN
LONG TERM LOAN | 12 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Long-term Debt [Text Block] | NOTE 5 LONG TERM LOAN As of June 30, 2021 and 2020, long term loan amounted to $582,159 and $0, respectively. The loan has an annual interest rate of 20%. The principal and interest are due in five years. Interest expense incurred for the years ended June 30, 2021 and 2020 amounted to $12,159 and $0, respectively. As of June 30, 2021, long term loan consisted of the following: Principal Imputed interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 7,014 $ 207.014 Received long term loan on June 3, 2021 290,000 4,290 294,290 Received long term loan on June 4, 2021 50,000 740 50,740 Received long term loan on June 23, 2021 30,000 115 30,115 Total $ 570,000 $ 12,159 $ 582,159 On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The issuance of these shares is recorded at fair market value of $0.00001 per share. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On June 18, 2021, the Company issued an aggregate of 2,950,000 shares to 6 unrelated parties as collateral for loans of $290,000. The issuance of these shares is recorded at fair market value of $0.00001 per share. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On May 31, 2021, the Company signed a loan agreement of $50,000 with an unrelated party, with 500,000 shares as collateral, and the company issued shares after receiving the proceed. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed of $20,000 on June 3, 2021.On June 18, 2021, the Company issued 200,000 shares to an unrelated party. The Company received the proceed of $30,000 on June 23, 2021. On October 28, 2021, the Company issued 240,000 shares to an unrelated party, and the remaining 60,000 shares have not been issued, On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The issuance of these shares is recorded at fair market value of $0.00001 per share. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. |
CONVERTIBLE, REDEEMABLE PREFERR
CONVERTIBLE, REDEEMABLE PREFERRED STOCK | 12 Months Ended |
Jun. 30, 2021 | |
Disclosure Text Block Supplement [Abstract] | |
Preferred Stock [Text Block] | NOTE 6 CONVERTIBLE, REDEEMABLE PREFERRED STOCK During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days. The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change. In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000. There were no preferred shares outstanding as of June 30, 2021 and 2020. |
SHAREHOLDERS' DEFICIT
SHAREHOLDERS' DEFICIT | 12 Months Ended |
Jun. 30, 2021 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 7 SHAREHOLDERS DEFICIT At June 30, 2021 and 2020, the Company had 21,070,866,399 and 20,236,021,836 shares issued and outstanding, respectively. 1) Shares issued for equity investment On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. The transaction has not been completed by the reporting date. Equity Investment in Purecell Group On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee.Becausethe company does not have significant control over Purecell, so this is an equity investment.Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. 2) Shares issued for stock compensation On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares was recorded at fair market value of $0.00001 per share.48,220,124 shares were issued at fair market value of $482. On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares was recorded at fair market value of $0.00001 per share. 79,362,534 shares were issued at fair market value of $794. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. 50,000,000 shares were issued at fair market value of $500. On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 6,621,905 shares were issued at fair market value of $66. On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 1,300,000 shares were issued at fair market value of $13. On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 7,140,000 shares were issued at fair market value of $71. On May 18 , 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus. On May 26, 2021, the Company issued 2,000,000 shares of common stock to Dr. Tsai as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 2,000,000 shares were issued at fair market value of $20. On May 26, 2021, the Company issued an aggregate of 450,000 shares of common stock to 3 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 450,000 shares were issued at fair market value of $5. On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at fair market value of $0.00001 per share. 11,300,000 shares were issued at fair market value of $113. 3) Shares issued for loan as collateral On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On June 18, 2021, the Company issued an aggregate of 2,950,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. |
EQUITY INVESTMENT
EQUITY INVESTMENT | 12 Months Ended |
Jun. 30, 2021 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | NOTE 8 EQUITY INVESTMENT On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Becausethe company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. The following table summarizes the income statement of Purecell. From date of equity investment to 06/30/2021 Sales $ 74,720 Gross profit 66,018 Net loss (50,965 ) 51% share (25,992 ) The following table provides the summary of balance sheet information for Purecell. As of June 30, 2021 Total assets $ 1,071,276 Net assets 1,071,276 51% ownership 546,351 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment - |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Jun. 30, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | NOTE 9 INCOME TAXES Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards. As of June 30, 2021, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset. Under the Provisional Regulations of The People’s Republic of China Concerning Income Tax on Enterprises promulgated by the PRC, which took effect on January 1, 2008, domestic and foreign companies pay a unified corporate income tax of 25%, except for a 15% corporate income tax rate for qualified high technology and science enterprises. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2021 and 2020 as follows: Year Ended June 30, 2021 2020 Income tax benefit at federal statutory rate-US 21 % 21 % State tax, net of fed effect-US 7 % 7 % Change in valuation allowance-US (28 )% (28 )% Income tax benefit at federal statutory rate-PRC 25 % 25 % Change in valuation allowance-PRC (25 )% (25 )% - % - % The components of deferred taxes consist of the following at June 30, 2021 and 2020: June 30, 2021 June 30, 2020 Net operating loss carryforwards $ 995,595 $ 238,591 Less: valuation allowance (995,595 ) (238,591 ) Net deferred tax assets $ - $ - As of June 30, 2021, the Company had federal and California income tax net operating loss carryforwards of $3,555,696. These net operating losses originating in tax years beginning prior to Jan. 1, 2018 will begin to expire 20 years from the date the tax returns are filed. The net operating losses originating in tax years beginning after Jan. 1, 2018 will be carry forwarded indefinitely. |
LEASE
LEASE | 12 Months Ended |
Jun. 30, 2021 | |
Disclosure Text Block [Abstract] | |
Lessee, Operating Leases [Text Block] | NOTE 10 LEASE The Company has entered into a operating leases agreement with GKT, Alhambra, LP. The lease term of the office space is from December 1, 2020 to November 30, 2023. The current monthly rent including monthly management fee is $4,655.64. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements. Operating lease right-of-use assets and liabilities commencing after December 1, 2020 are recognized at commencement date based on the present value of lease payments over the lease term. For the year ended June 30, 2021, the Company recognized approximately $32,589 in total lease costs. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Year Ended Cash paid for operating lease liabilities $ 32,589 Weighted-average remaining lease term 2.42 Weighted-average discount rate 5 % Minimum future lease payments $ 135,014 The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 2022 $ 55,868 2023 55,868 2024 23,278 2025 - 2026 - Total minimum payments 135,014 Less: imputed interest (8,087 ) Total lease liability 126,927 Less: short-term lease liability (50,672 ) Long-term lease liability $ 76,255 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Jun. 30, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 11 SUBSEQUENT EVENTS On September 3, 2021, America Great Health (the “Company”) entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626,286 for a purchase price of $7,000,000 (the “Agreement”). The purchase price shall be paid as follows : (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, America Great Health (the “Company”) entered into an Agreement with Wang’s Property Investment & Management LLC (“Wang”) to purchase some real estate properties held by Wang for a purchase price of $7,000,000. The Company and Wang have both agreed that they will not conduct due diligence in order for the transaction to proceed (the “transaction”, the “Agreement”). As of the reporting date, the Company has not made any payment for the transaction and the transaction has not completed. The properties acquired are commercial and residential properties located in Illinois for rental purposes. AAGH was purchased with a cash contribution of $7,000,000 and paid before April 10, 2022. The company will set up a management department or have professionals to manage and operate the property. On November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC. On November 11, 2021, America Great Health (the “Company”) entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD (“Consultant”). Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of GOF Biotechnologies Inc. / the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless terminated by either party pursuant to the Agreement. On November 15, 2021, the Company set up a 100% owned subsidiary Gof Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin will be appointed Chief Executive Officer of GOF. Shares issued for loan as collateral On May 31, 2021, the Company signed a loan agreement of $50,000 with an unrelated party, with 500,000 shares as collateral ,and the company issued shares after receiving the proceed. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed of $20,000 on June 3, 2021. On June 18, 2021, the Company issued 200,000 shares to an unrelated party. The Company received the proceed of $30,000 on June 23, 2021. On October 28, 2021, the Company issued 240,000 shares to an unrelated party, and the remaining 60,000 shares have not been issued. In October 2021, the Company issued 2,620,000 shares to 4 unrelated parties as collateral for loans of $170,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in July and September 2021. On October 28, 2021, the Company issued 100,000 shares to an unrelated party as collateral for a loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021. In November 2021, the Company issued 2,061,840 shares to 4 unrelated parties as collateral for loans of $202,138. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in October and November 2021. In November 2021, the Company signed 3 loan agreements of $80,000 with 3 unrelated parties, with 800,000 shares as collateral , and the company issued shares after receiving the proceed. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed of $80,000 in November 2021. As of the reporting date, these shares have not been issued. The Company received the proceed of $100,000 in November 2021. The company will sign 2 loan agreements with 2 unrelated parties, and the content of the agreement has not been determined as of the reporting date. The Company received the proceed of $100,000 in December 2021. The company will sign a loan agreement with an unrelated party, and the content of the agreement has not been determined as of the reporting date. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 12 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). |
Consolidation, Policy [Policy Text Block] | Basis of Consolidation The CFS includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California and US-China Mega Beauty Health Industry development Co., LTD, Intercompany transactions and accounts were eliminated in consolidation. |
Use of Estimates, Policy [Policy Text Block] | Estimates |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash The Company considers all highly liquid debt instruments purchased with maturity periods of six months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of June 30, 2021 and 2020, the Company’s bank account in the United States had $127,672 and $0, respectively, exceeding FDIC insurance of $250,000. |
Revenue [Policy Text Block] | Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. The Company has one major wholesale transaction with a new customer in the year ended June 30, 2021. Sales to this customer accounted for approximately 99% of total sales of the year ended June 30, 2021. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred to the customer as goods are delivered to the third party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed upon delivery to the third party carrier for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented. |
Inventory, Policy [Policy Text Block] | Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the years ended June 30, 2021 and 2020, the Company has not made provision for inventory in regards to slow moving or obsolete items. |
Equity Method Investments [Policy Text Block] | Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the year ended June 30, 2021. |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2021 and 2020, as there are no potential shares outstanding that would have a dilutive effect. |
Income Tax, Policy [Policy Text Block] | Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of June 30, 2021 and 2020. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements. |
OTHER RECEIVABLE (Tables)
OTHER RECEIVABLE (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Receivables [Abstract] | |
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] | As of June 30, 2021 and 2020, other receivable amounted to $61,136 and $0, respectively. Other receivable consists the following: June 30, 2021 June 30, 2020 Deposit for gas company $ 1,825 $ - Rent deposit 9,311 - Loan to a third party 50,000 - Total $ 61,136 $ - |
LONG TERM LOAN (Tables)
LONG TERM LOAN (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Long-term Debt Instruments [Table Text Block] | As of June 30, 2021, long term loan consisted of the following: Principal Imputed interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 7,014 $ 207.014 Received long term loan on June 3, 2021 290,000 4,290 294,290 Received long term loan on June 4, 2021 50,000 740 50,740 Received long term loan on June 23, 2021 30,000 115 30,115 Total $ 570,000 $ 12,159 $ 582,159 |
EQUITY INVESTMENT (Tables)
EQUITY INVESTMENT (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Equity Method Investments [Table Text Block] | The following table summarizes the income statement of Purecell. From date of equity investment to 06/30/2021 Sales $ 74,720 Gross profit 66,018 Net loss (50,965 ) 51% share (25,992 ) As of June 30, 2021 Total assets $ 1,071,276 Net assets 1,071,276 51% ownership 546,351 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment - |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ended June 30, 2021 2020 Income tax benefit at federal statutory rate-US 21 % 21 % State tax, net of fed effect-US 7 % 7 % Change in valuation allowance-US (28 )% (28 )% Income tax benefit at federal statutory rate-PRC 25 % 25 % Change in valuation allowance-PRC (25 )% (25 )% - % - % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | The components of deferred taxes consist of the following at June 30, 2021 and 2020: June 30, 2021 June 30, 2020 Net operating loss carryforwards $ 995,595 $ 238,591 Less: valuation allowance (995,595 ) (238,591 ) Net deferred tax assets $ - $ - |
LEASE (Tables)
LEASE (Tables) | 12 Months Ended |
Jun. 30, 2021 | |
Disclosure Text Block [Abstract] | |
Lease, Cost [Table Text Block] | Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Year Ended Cash paid for operating lease liabilities $ 32,589 Weighted-average remaining lease term 2.42 Weighted-average discount rate 5 % Minimum future lease payments $ 135,014 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 2022 $ 55,868 2023 55,868 2024 23,278 2025 - 2026 - Total minimum payments 135,014 Less: imputed interest (8,087 ) Total lease liability 126,927 Less: short-term lease liability (50,672 ) Long-term lease liability $ 76,255 |
NATURE OF BUSINESS (Details)
NATURE OF BUSINESS (Details) - USD ($) | Jul. 09, 2021 | May 11, 2021 | Dec. 07, 2020 | Jun. 30, 2020 | Jan. 19, 2017 | Jun. 30, 2021 | Jun. 30, 2020 | Apr. 06, 2021 | Feb. 10, 2021 | Jun. 30, 2019 |
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||
Stock Issued During Period, Shares, Acquisitions (in Shares) | 16,155,746,000 | |||||||||
Proceeds from Sales of Business, Affiliate and Productive Assets | $ 100 | |||||||||
Payments to Acquire Investments | $ 50,000 | |||||||||
Net Income (Loss) Attributable to Parent | $ (269,054) | $ (51,916) | ||||||||
Net Cash Provided by (Used in) Operating Activities | (329,241) | (39,559) | ||||||||
Stockholders' Equity Attributable to Parent | $ (215,007) | (467,827) | (215,007) | $ (168,002) | ||||||
Cash | $ 166 | $ 396,136 | $ 166 | |||||||
Corporate Joint Venture [Member] | ||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||
Equity Method Investment, Ownership Percentage | 60.00% | 51.00% | ||||||||
Payments to Acquire Interest in Joint Venture | $ 4,200,000 | |||||||||
Corporate Joint Venture [Member] | Brilliant Healthcare Limited [Member] | ||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||
Equity Method Investment, Ownership Percentage | 40.00% | |||||||||
Purecell Group [Member] | ||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||
Stock Issued During Period, Shares, Acquisitions (in Shares) | 31,212,000 | 510,000,000 | ||||||||
Equity Method Investment, Ownership Percentage | 51.00% | 51.00% | 51.00% | 51.00% |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | Jun. 30, 2021 | Jun. 30, 2020 |
Accounting Policies [Abstract] | ||
Cash, Uninsured Amount | $ 127,672 | $ 0 |
Cash, FDIC Insured Amount | $ 250,000 |
OTHER RECEIVABLE (Details)
OTHER RECEIVABLE (Details) - USD ($) | Jun. 30, 2021 | Jun. 30, 2020 |
Receivables [Abstract] | ||
Other Receivables | $ 61,136 | $ 0 |
Loans Receivable, Fair Value Disclosure | $ 50,000 | $ 0 |
OTHER RECEIVABLE (Details) - Sc
OTHER RECEIVABLE (Details) - Schedule of Accounts, Notes, Loans and Financing Receivable - USD ($) | Jun. 30, 2021 | Jun. 30, 2020 |
Schedule of Accounts, Notes, Loans and Financing Receivable [Abstract] | ||
Deposit for gas company | $ 1,825 | $ 0 |
Rent deposit | 9,311 | 0 |
Loan to a third party | 50,000 | 0 |
Total | $ 61,136 | $ 0 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - USD ($) | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Related Party Transactions [Abstract] | ||
Proceeds from Related Party Debt | $ 235,331 | |
Repayments of Related Party Debt | 79,608 | $ 82,217 |
Due to Related Parties, Current | 323,750 | 168,028 |
$ 7,885 | $ 4,911 |
LONG TERM LOAN (Details)
LONG TERM LOAN (Details) | Oct. 28, 2021shares | Jun. 23, 2021USD ($) | Jun. 18, 2021USD ($)$ / sharesshares | Jun. 03, 2021USD ($)shares | May 31, 2021USD ($)shares | May 26, 2021$ / shares | May 18, 2021$ / shares | May 05, 2021USD ($)$ / sharesshares | Apr. 07, 2021$ / shares | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Apr. 06, 2021$ / shares | Mar. 10, 2021$ / shares | Jan. 21, 2021$ / shares |
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||
Long-term Debt | $ 582,159 | $ 0 | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | |||||||||||||
Long-term Debt, Term | 5 years | |||||||||||||
Interest Expense, Debt | $ 12,159 | $ 0 | ||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | ||||||
Number of Unrelated Parties | 22 | 3 | 5 | 6 | 12 | |||||||||
Proceeds from Issuance of Debt | $ 570,000 | |||||||||||||
Loan #1 [Member] | ||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | |||||||||||||
Long-term Debt, Term | 5 years | |||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 10,000,000 | |||||||||||||
Debt Instrument, Face Amount | $ 200,000 | |||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | |||||||||||||
Debt Instrument, Payment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||
Loan #2 [Member] | ||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | |||||||||||||
Long-term Debt, Term | 5 years | |||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 2,950,000 | |||||||||||||
Debt Instrument, Face Amount | $ 290,000 | |||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | |||||||||||||
Number of Unrelated Parties | 6 | |||||||||||||
Debt Instrument, Payment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||
Loan #3 [Member] | ||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | 20.00% | ||||||||||||
Long-term Debt, Term | 5 years | |||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | 200,000 | 500,000 | |||||||||||
Debt Instrument, Face Amount | $ 50,000 | $ 50,000 | ||||||||||||
Proceeds from Issuance of Debt | $ 30,000 | $ 20,000 | ||||||||||||
Debt Instrument, Payment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||
Loan # 4 [Member] | ||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 240,000 | 200,000 | ||||||||||||
Proceeds from Issuance of Debt | $ 30,000 | $ 20,000 | ||||||||||||
Stock Shares not yet Issued (in Shares) | shares | 60,000 | |||||||||||||
Loan # 5 [Member] | ||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | |||||||||||||
Long-term Debt, Term | 5 years | |||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | |||||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | |||||||||||||
Debt Instrument, Payment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. |
LONG TERM LOAN (Details) - Sche
LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments - USD ($) | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Debt Instrument [Line Items] | ||
Principle | $ 570,000 | |
Imputed interest | 12,159 | $ 0 |
Balance | 582,159 | $ 0 |
Loan Received on April 27, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principle | 200,000 | |
Imputed interest | 7,014 | |
Balance | 207.014 | |
Loan Received on June 3, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principle | 290,000 | |
Imputed interest | 4,290 | |
Balance | 294,290 | |
Loan received on June 4, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principle | 50,000 | |
Imputed interest | 740 | |
Balance | 50,740 | |
Loan Received on June 23, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principle | 30,000 | |
Imputed interest | 115 | |
Balance | $ 30,115 |
LONG TERM LOAN (Details) - Sc_2
LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments (Parentheticals) | 12 Months Ended |
Jun. 30, 2021 | |
Loan Received on April 27, 2021 [Member] | |
Debt Instrument [Line Items] | |
Principle | Apr. 27, 2021 |
Loan Received on June 3, 2021 [Member] | |
Debt Instrument [Line Items] | |
Principle | Jun. 3, 2021 |
Loan received on June 4, 2021 [Member] | |
Debt Instrument [Line Items] | |
Principle | Jun. 4, 2021 |
Loan Received on June 23, 2021 [Member] | |
Debt Instrument [Line Items] | |
Principle | Jun. 23, 2021 |
CONVERTIBLE, REDEEMABLE PREFE_2
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) - Series A Preferred Stock [Member] - $ / shares | 12 Months Ended | |
Jun. 30, 2016 | Aug. 31, 2016 | |
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) [Line Items] | ||
Preferred Stock, Shares Authorized | 1,000,000 | 10,000,000 |
Preferred Stock, Dividend Rate, Percentage | 4.00% | |
Preferred Stock, Liquidation Preference Per Share | $ 1 | |
Preferred Stock, Redemption Terms | The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). | |
Preferred Units, Description | In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days |
SHAREHOLDERS' DEFICIT (Details)
SHAREHOLDERS' DEFICIT (Details) | Jun. 18, 2021USD ($)$ / sharesshares | Jun. 03, 2021shares | May 31, 2021USD ($)shares | May 26, 2021USD ($)$ / sharesshares | May 18, 2021USD ($)$ / sharesshares | May 11, 2021USD ($)$ / sharesshares | May 05, 2021USD ($)$ / sharesshares | Apr. 07, 2021USD ($)$ / sharesshares | Apr. 06, 2021USD ($)$ / sharesshares | Mar. 10, 2021USD ($)$ / sharesshares | Feb. 10, 2021shares | Jan. 21, 2021USD ($)$ / sharesshares | Jun. 30, 2020shares | Jan. 19, 2017shares | Jun. 30, 2021shares |
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Common Stock, Shares, Outstanding | 20,236,021,836 | 21,070,866,399 | |||||||||||||
Common Stock, Shares, Issued | 20,236,021,836 | 21,070,866,399 | |||||||||||||
Stock Issued During Period, Shares, Acquisitions | 16,155,746,000 | ||||||||||||||
Number of shareholders | 54 | 28 | |||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | $ 0.00001 | |||||||
Stock Issued During Period, Shares, Issued for Services | 11,300,000 | 450,000 | 7,140,000 | 1,300,000 | 6,621,905 | 50,000,000 | 79,362,534 | 48,220,124 | |||||||
Stock Issued During Period, Value, Issued for Services (in Dollars) | $ | $ 113 | $ 5 | $ 71 | $ 13 | $ 66 | $ 500 | $ 794 | $ 482 | |||||||
Number of Unrelated Parties | 22 | 3 | 5 | 6 | 12 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||
Dr. Tsai [Member] | |||||||||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | ||||||||||||||
Stock Issued During Period, Shares, Issued for Services | 2,000,000 | 8,000,000 | |||||||||||||
Stock Issued During Period, Value, Issued for Services (in Dollars) | $ | $ 20 | ||||||||||||||
Imediplus Inc. [Member] | |||||||||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Stock Issued During Period, Shares, Acquisitions | 70,000,000 | ||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 2,500,000 | ||||||||||||||
Equity Method Investment, Ownership Percentage | 5.00% | ||||||||||||||
Purecell Group [Member] | |||||||||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Stock Issued During Period, Shares, Acquisitions | 31,212,000 | 510,000,000 | |||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 510,000,000 | 510,000,000 | 510,000,000 | ||||||||||||
Equity Method Investment, Ownership Percentage | 51.00% | 51.00% | 51.00% | ||||||||||||
Number of shareholders | 2 | 2 | |||||||||||||
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture | 50,000,000 | ||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | |||||||||||||
Sale of Stock, Number of Shares Issued in Transaction | 71,163 | ||||||||||||||
Loan #1 [Member] | |||||||||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | ||||||||||||||
Stock Issued During Period, Shares, Other | 10,000,000 | ||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ | $ 200,000 | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||
Debt Instrument, Term | 5 years | ||||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | ||||||||||||||
Loan #2 [Member] | |||||||||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | ||||||||||||||
Number of Unrelated Parties | 6 | ||||||||||||||
Stock Issued During Period, Shares, Other | 2,950,000 | ||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ | $ 290,000 | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||
Debt Instrument, Term | 5 years | ||||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | ||||||||||||||
Loan #3 [Member] | |||||||||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Stock Issued During Period, Shares, Other | 500,000 | 200,000 | 500,000 | ||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ | $ 50,000 | $ 50,000 | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | 20.00% | |||||||||||||
Debt Instrument, Term | 5 years | 5 years | |||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||
Aussie Produce PTY LTD [Member] | Purecell Group [Member] | |||||||||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||||||||
Equity Method Investment, Ownership Percentage | 6.00% | ||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | ||||||||||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | $ | $ 2,340,000 | ||||||||||||||
Stock Issued During Period, Shares, New Issues | 35,000,000 | 35,000,000 | |||||||||||||
Sale of Stock, Number of Shares Issued in Transaction | 68,372 |
EQUITY INVESTMENT (Details)
EQUITY INVESTMENT (Details) - Purecell Group [Member] | May 26, 2021$ / sharesshares | May 11, 2021USD ($)$ / sharesshares | Apr. 06, 2021$ / sharesshares | Feb. 10, 2021shares | Jun. 30, 2020shares |
EQUITY INVESTMENT (Details) [Line Items] | |||||
Equity Method Investment, Ownership Percentage | 51.00% | 51.00% | 51.00% | ||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 510,000,000 | 510,000,000 | 510,000,000 | ||
Number of shareholders | 2 | 2 | |||
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture | 50,000,000 | ||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | |||
Sale of Stock, Number of Shares Issued in Transaction | 71,163 | ||||
Stock Issued During Period, Shares, Acquisitions | 31,212,000 | 510,000,000 | |||
Aussie Produce PTY LTD [Member] | |||||
EQUITY INVESTMENT (Details) [Line Items] | |||||
Equity Method Investment, Ownership Percentage | 6.00% | ||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | ||||
Proceeds from Issuance or Sale of Equity (in Dollars) | $ | $ 2,340,000 | ||||
Stock Issued During Period, Shares, New Issues | 35,000,000 | 35,000,000 | |||
Sale of Stock, Number of Shares Issued in Transaction | 68,372 |
EQUITY INVESTMENT (Details) - E
EQUITY INVESTMENT (Details) - Equity Method Investments - Corporate Joint Venture [Member] - USD ($) | 40 Months Ended |
Jun. 30, 2021 | |
Schedule of Equity Method Investments [Line Items] | |
Sales | $ 74,720 |
Gross profit | 66,018 |
Net loss | (50,965) |
51% share | (25,992) |
Total assets | 1,071,276 |
Net assets | 1,071,276 |
Share | 546,351 |
Beginning balance of investment | 5,450 |
Loss on equity investment | (5,450) |
Ending balance of investment | $ 0 |
EQUITY INVESTMENT (Details) -_2
EQUITY INVESTMENT (Details) - Equity Method Investments (Parentheticals) | Jun. 30, 2021 | Dec. 07, 2020 |
Corporate Joint Venture [Member] | ||
Schedule of Equity Method Investments [Line Items] | ||
51.00% | 60.00% |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
INCOME TAXES (Details) [Line Items] | ||
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | 15.00% | |
Operating Loss Carryforwards (in Dollars) | $ 3,555,696 | |
Foreign Tax Authority [Member] | ||
INCOME TAXES (Details) [Line Items] | ||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 25.00% | 25.00% |
INCOME TAXES (Details) - Schedu
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation [Line Items] | ||
State tax, net of fed effect | 7.00% | 7.00% |
Change in valuation allowance | (28.00%) | (28.00%) |
0.00% | 0.00% | |
Domestic Tax Authority [Member] | ||
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation [Line Items] | ||
Income tax benefit at federal statutory rate | 21.00% | 21.00% |
Foreign Tax Authority [Member] | ||
INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation [Line Items] | ||
Income tax benefit at federal statutory rate | 25.00% | 25.00% |
Change in valuation allowance | (25.00%) | (25.00%) |
INCOME TAXES (Details) - Sche_2
INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($) | Jun. 30, 2021 | Jun. 30, 2020 |
Schedule of Deferred Tax Assets and Liabilities [Abstract] | ||
Net operating loss carryforwards | $ 995,595 | $ 238,591 |
Less: valuation allowance | (995,595) | (238,591) |
Net deferred tax assets | $ 0 | $ 0 |
LEASE (Details)
LEASE (Details) - USD ($) | 12 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
LEASE (Details) [Line Items] | ||
Operating Lease, Expense | $ 39,679 | $ 0 |
Operating Lease, Cost | 32,589 | |
Minimum [Member] | ||
LEASE (Details) [Line Items] | ||
Operating Lease, Expense | $ 4,655.64 |
LEASE (Details) - Lease, Cost
LEASE (Details) - Lease, Cost | 12 Months Ended |
Jun. 30, 2021USD ($) | |
Lease, Cost [Abstract] | |
Cash paid for operating lease liabilities | $ 32,589 |
Weighted-average remaining lease term | 2 years 5 months 1 day |
Weighted-average discount rate | 5.00% |
Minimum future lease payments | $ 135,014 |
LEASE (Details) - Lessee, Opera
LEASE (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($) | Jun. 30, 2021 | Jun. 30, 2020 |
Lessee, Operating Lease, Liability, Maturity [Abstract] | ||
2022 | $ 55,868 | |
2023 | 55,868 | |
2024 | 23,278 | |
2025 | 0 | |
2026 | 0 | |
Total | 135,014 | |
Less: imputed interest | (8,087) | |
Total lease liability | 126,927 | |
Less: short-term lease liability | (50,672) | $ 0 |
Long-term lease liability | $ 76,255 | $ 0 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) | Nov. 11, 2021$ / sharesshares | Oct. 28, 2021shares | Sep. 03, 2021USD ($) | Jun. 23, 2021USD ($) | Jun. 18, 2021USD ($)shares | Jun. 03, 2021USD ($)shares | May 31, 2021USD ($)shares | May 26, 2021 | May 18, 2021 | May 05, 2021 | Apr. 07, 2021 | Nov. 30, 2021USD ($)shares | Oct. 31, 2021USD ($)shares | Jun. 30, 2021USD ($) | Dec. 31, 2021USD ($) | Nov. 15, 2021shares | Apr. 06, 2021 |
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||||
Proceeds from Issuance of Debt (in Dollars) | $ 570,000 | ||||||||||||||||
Number of Unrelated Parties | 22 | 3 | 5 | 6 | 12 | ||||||||||||
Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Number of Units in Real Estate Property | 53 | ||||||||||||||||
Payments to Acquire Real Estate (in Dollars) | $ 7,000,000 | ||||||||||||||||
Real Estate, Description of Terms | The purchase price shall be paid as follows : (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. | ||||||||||||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 500,000 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.01 | ||||||||||||||||
Warrants and Rights Outstanding, Term | 24 years | ||||||||||||||||
Equity Method Investment, Ownership Percentage | 100.00% | ||||||||||||||||
Investment Owned, Balance, Shares (in Shares) | shares | 20,000,000 | ||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 80,000 | $ 100,000 | |||||||||||||||
Proceeds from Issuance of Debt (in Dollars) | $ 100,000 | ||||||||||||||||
Number of Unrelated Parties | 2 | ||||||||||||||||
Number of loan agreements | 2 | ||||||||||||||||
Gof Biotechnologies, Inc. [Member] | Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 75.00% | ||||||||||||||||
Investment Owned, Balance, Shares (in Shares) | shares | 60,000,000 | ||||||||||||||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 25.00% | ||||||||||||||||
Imediplus Inc. [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Equity Method Investment, Ownership Percentage | 5.00% | ||||||||||||||||
Imediplus Inc. [Member] | Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Number of Real Estate Properties | 19 | ||||||||||||||||
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross (in Dollars) | $ 7,626,286 | ||||||||||||||||
Loan #3 [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 50,000 | $ 50,000 | |||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | 200,000 | 500,000 | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | 20.00% | |||||||||||||||
Debt Instrument, Term | 5 years | 5 years | |||||||||||||||
Proceeds from Issuance of Debt (in Dollars) | $ 30,000 | $ 20,000 | |||||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||
Loan #3 [Member] | Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 240,000 | ||||||||||||||||
Shares not yet issued (in Shares) | shares | 60,000 | ||||||||||||||||
Loan # 5 [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 50,000 | ||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||||
Loan # 5 [Member] | Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 170,000 | ||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 2,620,000 | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||||
Debt Instrument, Term | 5 years | ||||||||||||||||
Number of Unrelated Parties | 4 | ||||||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | ||||||||||||||||
Loan # 8 [Member] | Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 10,000 | ||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 100,000 | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||||
Debt Instrument, Term | 1 year | ||||||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | ||||||||||||||||
Loan #6 [Member] | Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 202,138 | ||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 2,061,840 | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||||
Debt Instrument, Term | 5 years | ||||||||||||||||
Number of Unrelated Parties | 4 | ||||||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | ||||||||||||||||
Loan # 7 [Member] | Subsequent Event [Member] | |||||||||||||||||
SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 80,000 | ||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 800,000 | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20.00% | ||||||||||||||||
Debt Instrument, Term | 5 years | ||||||||||||||||
Number of Unrelated Parties | 3 | ||||||||||||||||
Number of loan agreements | 3 | ||||||||||||||||
Long-term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. |